Abstract 1544P
Background
Patients (pts) with advanced gastric/gastroesophageal junction cancer that progresses on chemotherapy have poor outcomes. We investigated the safety and efficacy of camrelizumab combined with albumin-bound paclitaxel and S-1 in first-line treatment of HER-2-negative advanced gastric/gastroesophageal junction cancer.
Methods
This study was a single-arm, open-label, phase II clinical study. Eligible pts were adults with histologically confirmed HER-2 -negative advanced gastric/ gastroesophageal junction cancer. Pts participating in this study were required to detect PD-L1 expression, MSI/MMR status, and EBV virus content. Pts received camrelizumab (200 mg, day 1), S-1 (60mg/m2 bid, days 1-14), and albumin-bound paclitaxel (125mg/m2, days 1, 8) every 3 weeks. The maintenance therapy of camrelizumab (200 mg, day 1, every 3 weeks) was given to pts who did not progress after 4-6 cycles of chemotherapy until disease progression or unacceptable toxicity. Response was assessed every 6 weeks in accordance with RECIST1.1. The primary endpoint was overall response rate (ORR), and secondary endpoints included safety profile, progression free survival (PFS), overall survival (OS), and disease control rate (DCR).
Results
Between December 2020 and March 2023, a total of 28 pts were enrolled in this study. Median age was 57.5 (range: 35-71) years, and most pts were male (75.0%). Among 21 pts who were evaluated, the ORR was 71.4% (15/21) and the DCR was 95.2% (20/21). The median PFS was 9.3 months (95% Cl: 7.0-11.6), the Median follow-up time was 14.3 months (95% Cl: 9.9-18.7), and the one-year survival rate was 85.7%. The most common treatment-related adverse events of grade 3 or 4 included neutropenia (22.2%), leukopenia (22.2%), erythra (3.7%). There were no treatment-related deaths.
Conclusions
Camrelizumab plus albumin-bound paclitaxel and S-1 demonstrated promising activity and manageable safety in first-line treatment of HER-2- negative advanced gastric/gastroesophageal junction cancer.
Clinical trial identification
NCT04675866.
Editorial acknowledgement
Legal entity responsible for the study
Henan Cancer Hospital.
Funding
Jiangsu Hengrui Pharmaceutical Co. LTD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21